[Anti-mouse CD(52) antibody ameliorates colitis through suppressing Th1/17 mediated inflammation and promoting regulatory T cell response in interleukin-10 deficient mice].
In this study, we evaluated the therapeutic effects and possible mechanisms of anti-CD(5)2 treatment on interleukin-10 (IL-10) deficient mice. Anti-mouse CD(52) monoclonal antibody was administrated to C3H. IL-10(-/-)mice. The disease activity index, histological grading of colitis, serum Th1/17 related cytokines, percentage of CD(25+)Foxp3(+) T cells in colon as well as CD(25), Foxp3 gene expression were measured. Our data suggested that anti-CD(52) treatment inhibited colitis in C3H.IL-10(-/-)mice and it might be related to the suppression of Th1/17 related inflammation and the promotion of regulatory T cell differentiation.